Physician profile
John C Park
NPI 1255372827
$14,726.24
in general payments reported to CMS, 2019-2025
33 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,006 · 2021: $1,706 · 2022: $3,785 · 2023: $2,728 · 2024: $2,325 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,094 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,094.38 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $2,127.49 | 2022-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Sun Pharmaceutical Industries INC. | $1,524.59 | 2019-2025 | Cequa |
| Allergan, INC. | $1,181.15 | 2019-2022 | |
| Abbvie INC. | $1,119.95 | 2022-2025 | |
| Alcon Vision LLC | $1,080.45 | 2019-2025 | Tryptyr, Eysuvis, Argos |
| Glaukos Corporation | $1,030.40 | 2019-2024 | Idose |
| Bausch & Lomb Americas INC. | $943.95 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Aspire Iol |
| Oyster Point Pharma, INC. | $781.73 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $687.52 | 2019-2023 | |
| Sight Sciences, INC. | $582.36 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Mallinckrodt Hospital Products INC. | $495.50 | 2021-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $434.79 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $392.10 | 2020-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Ocular Therapeutix, INC. | $356.57 | 2022-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $347.48 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $227.39 | 2024-2025 | Vevye |
| Dompe US, INC. | $208.07 | 2019-2025 | Oxervate |
| Notal Vision, INC. | $202.47 | 2021 | |
| Ani Pharmaceuticals, INC. | $132.81 | 2022-2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $129.22 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $113.69 | 2019-2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $100.64 | 2019-2021 | |
| Shire North American Group INC | $85.77 | 2019 | |
| Thea Pharma INC. | $82.05 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $76.07 | 2022 | |
| Coopervision INC. | $70.21 | 2019 | |
| Amgen INC. | $53.17 | 2025 | Tepezza |
| Ivantis, INC | $45.58 | 2020-2021 | |
| Aerin Medical INC. | $36.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $28.76 | 2019 | |
| Alimera Sciences, INC. | $16.94 | 2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $16.20 | 2025 | Syfovre |
| Eyepoint US, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.